CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
2.130
+1.202 (129.43%)
At close: May 12, 2025, 4:00 PM
1.980
-0.150 (-7.04%)
After-hours: May 12, 2025, 7:59 PM EDT
CytomX Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CytomX Therapeutics stock has a target of 2.50, which predicts a 17.37% increase from the current stock price of 2.13.
Price Target: $2.50 (+17.37%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for CytomX Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $3.25 → $2.5 | Buy | Maintains | $3.25 → $2.5 | +17.37% | Apr 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jan 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Sep 13, 2024 |
Financial Forecast
Revenue This Year
101.22M
from 138.10M
Decreased by -26.71%
Revenue Next Year
29.82M
from 101.22M
Decreased by -70.54%
EPS This Year
0.01
from 0.38
Decreased by -97.64%
EPS Next Year
-0.61
from 0.01
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 163.3M | 107.1M | 52.5M | ||
| Avg | 101.2M | 29.8M | 18.2M | ||
| Low | 49.0M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 18.2% | 5.8% | 76.0% | ||
| Avg | -26.7% | -70.5% | -39.0% | ||
| Low | -64.5% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 0.29 | 0.15 | -0.53 | |
| Avg | 0.01 | -0.61 | -0.65 | |
| Low | -0.43 | -0.99 | -0.83 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -23.5% | 1,547.1% | - | |
| Avg | -97.6% | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.